Powers Advisory Group’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.04M Sell
2,216
-78
-3% -$79.1K 0.72% 26
2025
Q4
$2.47M Buy
2,294
+7
+0.3% +$6.69K 0.93% 20
2025
Q3
$1.74M Sell
2,287
-2
-0.1% -$1.49K 0.69% 27
2025
Q2
$1.78M Buy
2,289
+3
+0.1% +$2.33K 0.78% 25
2025
Q1
$1.89M Sell
2,286
-62
-3% -$51.6K 0.9% 21
2024
Q4
$1.81M Sell
2,348
-19
-0.8% -$15.7K 0.91% 21
2024
Q3
$2.1M Buy
2,367
+71
+3% +$63.8K 1.05% 20
2024
Q2
$2.08M Buy
2,296
+8
+0.3% +$6.4K 1.13% 20
2024
Q1
$1.78M Buy
2,288
+58
+3% +$41.3K 1.02% 19
2023
Q4
$1.3M Sell
2,230
-1,082
-33% -$632K 0.8% 25
2023
Q3
$1.78M Sell
3,312
-237
-7% -$122K 1.21% 20
2023
Q2
$1.66M Buy
3,549
+3
+0.1% +$1.26K 1.1% 21
2023
Q1
$1.22M Sell
3,546
-5
-0.1% -$1.69K 0.85% 28
2022
Q4
$1.3M Sell
3,551
-312
-8% -$111K 0.96% 26
2022
Q3
$1.25M Buy
3,863
+8
+0.2% +$2.54K 1% 25
2022
Q2
$1.25M Sell
3,855
-141
-4% -$42.3K 0.96% 24
2022
Q1
$1.14M Sell
3,996
-5
-0.1% -$1.29K 0.8% 28
2021
Q4
$1.1M Buy
+4,001
New +$1.01M 0.78% 30

Other funds holding LLY

Powers Advisory Group's LLY Position: Q1 2026 in Review

Powers Advisory Group reduced its Eli Lilly (LLY) stake by 3.4% in Q1 2026, selling an estimated $79.1K and leaving 2,216 shares worth $2.04M. The position accounts for 0.72% of the portfolio, ranked #26.

Powers Advisory Group first reported a position in LLY in Q4 2021 and has held it in 18 quarters since. The position peaked at $2.47M in Q4 2025. 4,352 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Powers Advisory Group held 2,216 shares of Eli Lilly worth $2.04M as of Q1 2026.
  • Powers Advisory Group sold 78 Eli Lilly shares in Q1 2026, an estimated $79.1K.
  • Eli Lilly made up 0.72% of Powers Advisory Group's portfolio in Q1 2026, its #26 holding.
  • Powers Advisory Group first reported a position in Eli Lilly in Q4 2021 and has held it in 18 quarters since.
  • Powers Advisory Group's Eli Lilly position peaked at $2.47M in Q4 2025.
  • 4,352 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Powers Advisory Group's 13F filing for Q1 2026, filed 21 Apr 2026.